Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner (Journal of Immunology (2010) 184, (1092-1101))

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 5414-

  Izhak, Liat ^a   Wildbaum, Gizi ^a   Weinberg, Uri ^a   Shaked, Yuval ^a   Alami, Jennifer ^c   Dumont, Daniel ^c   Friedman, Boris ^b   Stein, Avi ^b   Karin, Nathan ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERRATUM; ERROR; PRIORITY JOURNAL;

EID: 77955369369     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1090025     Document Type: Erratum

References (0)